KEITH KROM PARKER
Associate Professor of Pharmacology and Toxicology
College of Health Professions and Biomedical Sciences
Skaggs School of Pharmacy
Department of Biomedical and Pharmaceutical Sciences (BMED)
Center for Structural and Functional Neuroscience (CSFN)
The University of Montana
Missoula, Montana 59812-1552
406-243-4235; 406-243-6498; keith.parker@umontana.edu
Professional Summary: Neuropharmacologist; Neurochemist; primary
basic research interests in serotonin receptor systems; primary
applied research interest in development of superior anti-migraine
drugs; research methodologies focusing on neural cell culture
systems in association with molecular biological techniques;
receptor binding assays and signal transduction systems.
Employment History:
University of Montana:
1-1-93 to present.
Western Montana College: 8-1-81 to 12-31-92; Assist., Assoc., and
Full Professor of Chemistry; Dean of Faculty, 4/1/8912/31/92.
University of Denver:
11-1-79 to 6-30-81; Research Associate,
Department of Chemistry; laboratory of Dr. Eric Wickstrom.
University of Colorado Health Sciences Center, Denver: 10-1-77 to
9-30-79; Post-doctoral Fellow, Department of Pharmacology;
laboratory of Dr. Antonia Vernadakis.
Education:
University of California, San Francisco: Ph.D., September 1977;
Department of Pharmacology and Toxicology; laboratory of Dr.
Anthony Trevor.
Montana State University, Bozeman,
Department of Psychology.
MT:
B.S.,
March
Scientific Societies (Past and Present Memberships):
American Association for the Advancement of Science
American Chemical Society
American Society of Pharmacognosy
Montana Academy of Sciences
1972;
Sigma Xi: The Scientific Research Society
Society for Neuroscience
Western Pharmacology Society
Funding History:
American Cancer Society Institutional Grant (MSU): "Regulation of
Differentiation in C-6 Glioma." $4,200; 1989-1990.
University of Montana Grants Program (UM): "Retinoblastoma as a
Potential Drug Screening System." $2,200; 1993.
NSF
EPSCoR:
"Molecular Pharmacology of the 5HT1a Receptor."
$82,071; 1993-1996. (E. Dratz, P.I. of the parent grant; MSU)
American Gloxinia & Gesneriad Society: “Migraine Remedies from
South American Plants.” $1,500; 1996-1997. (With E. Russo &
R. Medora)
Multidisciplinary Assoc. for Psychedelic Studies: “Migraine
Remedies from Psychoactive Plants.” $2,500; 1996-1997. (With
E. Russo & R. Medora)
NIH
AREA:
"Peptide Probes of the
Interface." $75,000; 1996-1999.
5HT1a
Receptor-G
Protein
NIH Minority Student (Marvin Devereaux) Supplement:
$6,443: 1997-1998; $6,443: 1998-1999; total: $12,886.
NIH AREA: “Peptide Probes of the
Interface.” $75,000; 1999-2002.
5HT1a
Receptor-G
Protein
NIH COBRE: “Structural Elucidation of the 5HT1a Receptor-G
Protein Interface.” $110,614/year; 2000-2004.
Honors:
American Men and Women in Science (1982-present)
Special Service Award:
Montana Federation of Teachers (1987;1989)
Mershon Award: Montana Academy of Sciences, 2001.
Professional Service:
Chairperson, Montana Section, American Chemical Society (1992-93);
Treasurer (1987-1991).
Member, Focus Group on Biotechnology:
Technology Plan (1992).
President,
U.
of
Montana
Chapter:
Sigma
Montana
Xi,
Science
The
and
Scientific
Research Society (1996-1997).
President, Montana Academy of Sciences (1988-1989); Sectional
Vice-President, Pharm. and Tox. Sci. (1984-1987; 2003-2004);
Treasurer (2006-2010).
Board
of Directors,
1989).
Western
Montana
College
Foundation
(1986-
President, Western Montana College Fac. Assoc. (1983-1987).
Board of Directors, Murdoch Molecular Biology Facility, U. of
Montana (1998-2002)
Peer
Review
(ad
hoc):
Science;
Neurochemical
Research;
Developmental
Neuroscience;
International
Journal
of
Developmental Neuroscience; Journal of Neuroscience Research;
Molecular and Cellular Biology; Journal of Spinal Cord
Medicine; Journal of Cerebral Blood Flow and Metabolism; U.S.
Department of Defense; Neurochemistry International; Journal
of Neuroscience; Life Sciences; Recent Patents on CNS Drug
Discovery; J. Neurochem; Central Nervous System Agents in
Medicinal Chemistry; J. Proteomics and Bioinformation;
Journal of Nutrition, Health, and Aging.
Member, Editorial Board, J. of Thermodynamics and Catalysis
Member, Editorial Board, Data Set Papers in Pharmacology
Consultant: Mylan Laboratories
Member, Collective Bargaining Team; U. Fac. Assoc., 2010-2012.
Outside Reviewer: Tenure Application from the U. of Colorado,
2011; 2014; Texas A & M College of Pharmacy, 2015.
Presentations:
February, June, September, and December 2014; February, June,
and September, 2015: Radiation Safety Training; University of
Montana.
April 2013: CSFN Research Seminar Series, University
Montana. “A Small Library of 5HT1a Receptor Ligands.”
of
February 2012: School of Pharmacy, University of Montana.
“Migraine Headache: Cardiovascular Disease.”
February 2011: School of Pharmacy, University of Southern
California. “Peptide and Non-Peptide Interactions at the
Human 5HT1a Receptor.”
March 2008: University of Catania; Sicily. “Exploring the
Human 5HT1a Receptor-G Protein Interface.”
March 2008: University of Catania; Sicily. “Synthetic and
Natural Product Probes of the Human 5HT1a Receptor.”
May 2007: In Service to U. of Montana Psychology Faculty
and Graduate Students. “A Review of Psychotropic Drugs.”
October 2006: Brain and Learning Conference, Great Falls,
MT.
“The
Neurobiology
of
Depression:
Affective
Disorders.”
October 2006: Brain and Learning Conference, Great Falls,
MT. “Window on the Human Brain: Portal to the Future.”
June 2004: Montana Neuroscience Retreat, Seeley Lake, MT.
“Serotonin Receptors: Future Studies.”
February 2004: Recent Advances in Clinical Medicine, School
of Pharmacy and Allied Health Sciences, The University of
Montana. “The Pathophysiology and Neurobiology of Pain.”
October 2003: Montana Neuroscience Institute Foundation
Public Lecture Series, St. Patrick Hospital and Health
Sciences Center, Missoula, MT. “Oh What a Headache:
Unraveling the Complexities of Migraine.”
June 2003: Montana Neuroscience Retreat, Seeley Lake, MT.
“5HT1a Receptor Intracellular Loop-G Protein Interactions.”
December 2002: Supply Side West, Las Vegas, NV. “The Promise
of Promilin.” (With Jerry R. Smith and Dick Hynson)
October 2002: Western Montana College of the University
of Montana, Dillon, MT. “Drugs and the Nervous System.”
June 2002: Montana Neuroscience Retreat, Seeley Lake, MT.
“5HT1a Receptor Intracellular Loop-G Protein Interactions.”
June 2001: 56th Northwest Regional Meeting of the American
Chemical Society, Seattle, WA.”Coupling and Activation at
the Human 5HT1a Receptor-G Protein Interface.”
December 2000: Division of Biological Sciences, U.M. “A
Model of the Human 5HT1a Receptor-G Protein Interface.”
May 2000: 2nd Annual Montana Neuroscience Conference, Salmon
Lake. “A Model of the Human 5HT1a Receptor-G Protein
Interface.”
October 1997: Dept. of Pharm., Toxicol, and Therap., U. of
Kansas Medical Center.
"The 5HT1a Receptor-G Protein
Interface."
August 1997: Dept. of Biol., and Program for Neurosciences, U. of
Utah. "The 5HT1a Receptor-G Protein Interface."
March 1997: Dept. of Pharm. Sci., U.M.
Protein Interface."
"The
5HT1a Receptor-G
April 1996: Research Colloquium, Western Montana College of the
University of Montana. "What a Headache: The Development of
Anti-Migraine Drugs."
November 1995: Dept. of Chemistry,
of 5HT1a and 5HT2a Receptors."
April
U.M.
"Molecular Pharmacology
1995:
Dept. of Chem. and Biochem., M.S.U.
Receptor Subtypes as Anti-Migraine Drug Targets."
"Serotonin
March 1995: Western Montana Clinic, Polson. "Recent Developments
in the Pharmacotherapy of Migraine Headache."
February 1995:
Dept.
of Pharm. Sci.,
Pharmacology of 5HT1a Receptors."
July
U.M.
"Molecular
1994:
Canyon Ferry Limnological Institute,
"Perspectives in Neuropharmacological Research."
April 1993: Sigma Xi Seminar Series, U.M.
Migraine Drugs from Natural Products."
Helena.
"The Search for Anti-
April 1992: Dept. of Pharm. Sci., U.M. "Ornithine Decarboxylase
Activity in Primary Neural Cell Culture."
October 1989:
Dept. of Chem., Montana Tech.
Differentiation in C6 Glioma."
"Regulation of
February 1988: Dept. of History and Philosophy, Montana State
University. “New Concepts in Chemical and Biological
Warfare.”
March
May
1987: Dept. of History and Philosophy, Montana State
University. “Recent Trends in Chemical and Biological
Warfare.”
1986:
St. Peters
Neuropharmacology."
Hospital,
Helena.
"Recent
Trends
in
February 1986: Dept. of History and Philosophy, Montana State
University. “Understanding the Basics in the Development of
Chemical and Biological Warfare.”
February
1985:
Regional
Conference
for
Mental
Health
Professionals, Great Falls, Mt. Basic Pharmacology Related to
Psychiatric Disorders.”
February 1984: Dept. of History and Philosophy, Montana State
University. “The Nature of Chemical and Biological Warfare in
the 20th Century.”
December 1983:
Ribosomes:
Dept. of Chem., U.M.
"Molecular Rulers for
Studies with Chlorambucil Modified Transfer RNA."
March 1983: Dept. of Chem., Montana Tech. "Molecular Rulers for
Ribosomes:
Studies with Chlorambucil Modifified Transfer
RNA."
October 1982:
Ribosomes:
Dept. of Chem., M.S.U.
"Molecular Rulers for
Studies with Chlorambucil Modified Transfer RNA."
April 1981: Dept. of Biol., U. of Denver. “Transdifferentiation of
C6 Glioma Cells in Culture.”
March
1981:
School
of
Pharmacy,
Washington
State
"Transdifferentiation of C6 Glioma Cells in Culture."
U.
February 1981:
U. of South Dakota School of Med.
"Molecular
Rulers for Ribosomes:
Studies with Chlorambucil Modified
Transfer RNA."
February 1980: U. of South Dakota School of Med. "Stimulation of
Ornithine Decarboxylase Activity in Neural Cell Culture."
February 1979:
U. of Colo. Hlth. Sci. Center. "Stimulation of
Ornithine Decarboxylase Activity in Neural Cell Culture."
January 1979: Winter Conference on Brain Research, Sun Valley, ID.
“Neuropharmacology of Anti-Convulsant Drugs.”
September 1977: UCSF. "Active Site Studies with Native Forms of
Electric Eel Acetylcholinesterase."
Invited Meetings:
January 1994:
Biology."
Gordon
Conference,
Oxnard
CA:
"Pineal
Cell
August 1989:
35th Gen. Assembly of IUPAC, Lund, Sweden.
Corresponding Member of the Commission on Toxicology.
August 1987:
34sth Gen. Assembly of IUPAC, Boston,
Corresponding Member of the Commission on Toxicology.
MA.
Publications:
Alfonsino, G.E., Santagati, A., Basile, L., Novellino, E.,
Gaul, C., Squires, C., Braden, M., Gerdes, J. M., Silanes, S.P.,
Guiccione, S., and Parker, K.K. 5HT1a
Binding Affinities of a
Series of Serotonin Transporter
(SERT) Inhibitors and Related
Thermodynamic Insights. Journal of Advances in Medical and
Pharmaceutical Sciences 4(1): pgs. 1-12, 2015. Article No.
JAMPS.18917.
DOI:10.9734/JAMPS/2015/18917.
Hall, B., Squires, C., and Parker, K.K. “Intracellular Loop
Peptides of the Human 5HT1a Receptor are Differential
Activators of Gi.” Int. J. Peptides, Vol.2012, Article ID
490734. doi:10.1155/2012/490734.
Hall, B., Burnett, A., Christians, A., Halley, C., Goldstein,
E., Thiagaraj, H.V., and Parker, K.K. “Thermodynamics of
Peptide and Non-Peptide Interactions with the Human 5HT1a
Receptor.” Pharmacology 86 (1): 6-14, 2010.
Nieh, M.T., and Parker, K.K. "Spearmint (MENTHA SPICATA,
LAMIACEAE) As a Potential Antimigraine Remedy: A Personal
Anecdote." J. Alt. Compl. Med. 13 (10): 1161-1162, 2007.
Thiagaraj, H.V., Ortiz, T.C., Devereaux, M.C. Jr., Seaver,
B., Hall, B., and Parker, K.K. “Regulation of G Proteins by
Human 5-HT1a Receptor TM3/i2 and TM5/i3 Loop Peptides.”
Neurochemistry International 50: 109-118, 2007.
Russo, E.B., Burnett, A., Hall, B., and Parker, K.K.
“Agonistic Properties of Cannabidiol at 5-HT1A Receptors.”
Neurochem. Res. 30 (8): 1037-1043, 2005.
Smith, J.R., Thiagaraj, H.V., Seaver, B., and Parker, K.K.
“Differential Activity of Lipoic Acid Enantiomers in Cell
Culture.” J. Herbal Pharmacoth. 5 (3): 43-54, 2005.
Thiagaraj, H.V., Thompson, C.M., Russo, E.B., Burnett, A.,
Goldstein, E., and Parker, K.K. “Binding Properties of
Dipropyltryptamine at the Human 5HT1a Receptor.” Pharmacology
74: 193-199, 2005.
Stierle, A.A., Stierle, D.B., Goldstein, E., Parker, K.,
Bugni, T., Baarson, C., Gress, J., and Blake, D. “A Novel 5HT Receptor Ligand and Related Cytotoxic Compounds from an
Acid Mine Waste Extremophile.” J. Nat. Prods. 66 (8): 10971100, 2003.
Thiagaraj, H.V., Ortiz, T.C., Burnett, A., and Parker, K.K.
“G Protein Coupling and Activation Characteristics of
Intracellular Loops 2 and 3 of the 5HT1a Receptor.” Trends in
Comp. Biochem. and Physiol. 9: 117-129,2002.
Ortiz,
T.C.,
Devereaux,
M.C.,
and
Parker,
K.K.
“Structural
Variants
of
a
Human
5HT1a
Receptor
Intracellular Loop 3 Peptide.” Pharmacology 60: 195-202,
2000.
Hayataka, K., O'Connor, M.-F., Kinzler, N., Weber, J.T., and
Parker,
K.K.
"A
Bioactive
Peptide
from
the
Transmembrane5/Intracellular Loop 3 Region of the Human 5HT1a
Receptor." Biochem. Cell Biol. 76(4): 657-660, 1998.
Weber, J.T., Hayataka, K., O'Connor, M.-F., and Parker, K.K.
"Rabbit Cerebral Cortex 5HT1a Receptors."
Comp. Biochem.
Physiol. 117C: 19-24, 1997.
Weber, J.T., O'Connor, M.-F., Hayataka,
K., Colson, N.,
Medora, R., Russo, E.B., and Parker, K.K.
"Activity of
Parthenolide at 5HT2a Receptors." J. Nat. Prods. 60: 651654, 1997.
Russo, E.B., Medora, R., Parker, K., and Thompson, C. “An
Investigation of Psychedelic Plants and Compounds for
Activity in Serotonin Receptor Assays for Headache Treatment
and Prophylaxis.” MAPS 7 (1): 4-8, 1996.
Anders, P., Dahy, N., Kieckbusch, J., Passuccio, L., and
Parker, K. “A Mini-Review of the Pharmacology and Toxicology
of Cocaine.” Proc. of the Montana Academy of Sciences 50: 97107, 1990.
Parker, K., et al. "A mini-review of the Pharmacology and
Toxicology of Marijuana." Proceedings of the
Montana
Academy of Sciences, 47: 89-97, 1987.
Vernadakis, A., Sakellaridis, N., Mangoura, A., Davies,
D.
and Parker, K.
"Cellular and Molecular Aspects of
Glial Cells with Aging."
Advances in the Biosciences 61:
371-379, 1986.
Parker, K., Carlin, R., Griffen, W., Kelley, D., Konen,
J.,Miller, C., and Williams, L.
"A Review of the
Pharmacological,
Societal,
and
Therapeutic
Aspects
of
Phencyclidine Use."
Proceedings of the Montana Academy
of
Sciences, 44: 45-51, 1984.
3H-
Parker, K., and Wickstrom, E. "Identification of
ribosomal
proteins and RNA's alkylated by
chlorambucilylpentaproylphenylalanyl-tRNA." Nucleic
Acids Research, 11:
515-524,
1983.
Vernadakis, P., Parker, K., Arnold, E.B., and Norenberg,
M.D.
"Role of Glial Cells in CNS Aging."
In The Aging
Brain:
Cellular and Molecular Mechanisms of Aging in the
Nervous System, Raven Press, New York, 1982.
Wickstrom, E., Parker, K., Hursh, D.A., and Newton, R.L.
"Chlorambucilyl 3H Phenylalanyl-tRNA crosslinking to 50s
ribosomal subunit proteins L4, L18-20, and L26-27."
FEBS
Letters, 123: 273-276. 1981.
Vernadakis, A., Parker, K., and Norenberg, M. “Changes in
Biochemical Properties of Glial Cells in Culture: In
Vitro
Differentiation.” In Tissue Culture in
Neurobiology(E.Giacobini
et al., Eds.). Raven Press, New
York, 1980.
Vernadakis, A., and Parker, K.
"Drugs and the Developing
central nervous system."
Pharmacology and Therapeutics,
11:593-647, 1980.
Parker, K., and Vernadakis, A.
"Stimulation of Ornithine
Decarboxylase Activity in Neural Cell Culture:
Potential
Role of Insulin." J. Neurochem. 35: 155-163, 1980.
Parker,
K.K.,
Norenberg,
M.D.,
and
Vernadakis,
A.
"Transdifferentiation of C-6 Glial Cells in Culture."
Science 208: 179-181, 1980.
Parker, K.K., and Trevor, A.J. “Active Site Stoichiometry Of
Native Forms of Eel Acetylcholinesterase.” Proc. West.
Pharmacol. Soc. 21: 221-222, 1978.
Parker, K.K., Chan, S.L., and Trevor, A.J. "Purification of
the Native Forms of Acetylcholinesterase:
Active Site
Determination."
Arch. Biochem. Biophys.
187:
322-327,
1978.
Trevor, A.J., Gordon, M.A., Parker, K.K., and Chan, S.L.
"Acetylcholinesterases." Life Sci. 23: 1209-1220, 1978.
Greenberg,
A.G.,
Parker,
K.K.,
and
Trevor,
A.J.
"Immunochemical
Studies
of
Mammalian
Brain
Acetylcholinesterase." J. Neurochem. 29: 911-917, 1977.
Abstracts:
Basile, L., Guccione, S., Squires, C., Gaul, C., and
Parker, K.K. “Insights Into the Thermodynamic Properties
of
a
5HT1a
Receptor
Ligand.”
GLISTEN
(GPCR-Ligand
Interactions, Structures, and Transmembrane Signalling-A
European Research Network) Conference, Budapest, Hungary,
P410, pg. 72; October, 2014.
Guccione, S., Basile, L., Squires, C., Gaul, C., and Parker,
K.K. “Thermodynamic Properties of a 5HT1a Receptor Ligand.”
69th Northwest Regional Meeting of the American Chemical
Society (NORM). No. 81, pg. 24, 2014.
Parker, K.K., Hall, B., Rama Rao, K.V., Jayakumar, A.R.,
Panickar, K.S., and Norenberg, M.D. “Serotonin Receptors in
Differentiated Primary Rat Brain Astrocyte Culture.” Soc.
Neurosci. Absts. 38: 340.16, 2011.
Villarreal-Calderon, R., Palacios-Moreno, J., Parker, K.,
and Calderon-Garciduenas, L.“Geneinflammatory expression
profiling in right versus left ventricles in young
urbanites: what is the long-term impact of myocardial
inflammation in the setting of air pollution?”Experimental
Biology: 1029.1, 2010
Guccione, S., and Parker, K.K. “Activity of a Series of SERT
Inhibitors at the Human 5HT1a Receptor in Culture.” Ann.
Meeting of the Montana Academy of Sciences, April 2009.
Hall, B., Squires, C., and Parker, K.K. “Thermodynamics
of Human 5HT1a Receptor Loop 2 Peptides.” Soc. for
Neurosci. Absts. 33: 465.8, 2007.
Nieh, M.T., and Parker, K.K. “A Personal Anecdote with
Spearmint (Mentha spicata) as Migraine Prophylaxis.” Am. Soc.
Pharmacog. Absts. 48: 2007.
Hall, B., Squires, C., Burgstrom, J., and Parker, K.K. q
“Human 5HT1a Receptor Loop 2 TM4: Structure-Activity.”
American
Indians
in
Science
and
Engineering
Society
National Conference, Detroit, MI, 2006.
Hall, B., Madden, L., and Parker, K.K. “Cell Volume
Regulation By the Human 5HT1a Receptor.” Scientific Res. Soc.
Absts., PR-04, 2006
Hall, B., Squires, C., Burgstrom, J., and Parker, K.K.
“Human 5HT1a Receptor Loop 2 TM4: Structure-Activity.” Soc.
for Neurosci. Absts. 32: 33.14/C6, 2006.
Hall, B., Christians, A., Parker, L.A., and Parker, K.K.
“Loop 2 of the 5HT1a Receptor: Coupling and Activation.” Soc.
for Neurosci. Absts. 31: 373.10, 2005.
Hall,
L.A.,
5HT1a
P:85,
B., Burnett, A., Halley, C., Christians, A., Parker,
Medora, R., and Parker, K.K. “Pharmacology of Bacopa at
and 5HT2a Receptors.” Am. Soc. of Pharmacog. Absts. 46:
2005.
Russo, E.B., Burnett, A., Hall, B., Christians, A., Halley,
C., Parker, L.A., and Parker, K.K. “Differential Activity of
Cannabidiol and Tetrahydrocannabinol at 5HT1a Receptors.”
Int. Cannabinoid Res.Soc. Absts. 49: 2005.
Seaver, B., Smith, J. and Parker, K. “The Insulinogenic
Potential of Fenugreek and Lipoic Acid Enantiomers in Glucose
Sensing HIT-T15 Immortalized Beta Cells.” National Conference
on Undergraduate Research (NCUR): Indianapolis, IN, 2004.
Burnett, A., Hall, B., Christians, A., Halley, C., Parker,
L.A., and Parker, K.K. “Intracellular Loop Peptide Libraries
for the 5HT1a Receptor.” Soc. for Neurosci. Absts. 30:
394.14, 2004.
Hall, B., Burnett, A., Christians, A., Halley, C., Parker,
L., Russo, E., and Parker, K.K. “Pharmacology of Cannabidiol
at Serotonin Receptors.” Proc. West. Pharmacol. Soc. 47: 43
(M-24), 2004.
Burnett, A., Goldstein, E., Hall, B., Christians, A., and
Parker, K.K. “Binding Thermodynamics of Human 5HT1a Receptor
Ligands.” Soc. for Neurosci. Absts, 29: 362.18, 2003.
Thiagaraj, H.V., Burnett, A., Hall, B., Seaver, B., Sakaske,
S., and Parker, K.K. “A 5HT1a Receptor Peptide Regulates GTP
Incorporation into Gi.” Soc. for Neurosci. Absts. 28: 741.5,
2002.
Smith, J.R., Thiagaraj, H.V., and Parker, K.K. “Differential
Activity of Lipoic Acid Enantiomers in Cell Culture.” XIV
World Congress of Pharmacology (IUPHAR) Absts., 109.6, 2002.
Russo, E., Ben-Shabat, S., Fride, E., Parker, K., and
Mechoulam, R. “In Search of Plants, Other than Cannabis
Sativa, With Cannabinoid Activity.” Int. Cannabinoid Res.
Soc. Absts. 46: 2002.
Thiagaraj, H.V., Ortiz, T., and Parker, K. “Coupling and
Activation at the Human 5HT1a Receptor-G Protein Interface.”
Am. Chem. Soc. NW Reg.56: 159, 2001.
Thiagaraj, H.V., Russo, E.B., Thompson, C.M., and Parker,
K.K.“Pharmacology of Dipropyltryptamine at Human 5HT1a
Receptors.” Soc. for Neurosci. Absts. 27: 266.7, 2001.
Ortiz, T.C., Devereaux, M.C., Thiagaraj, H.V., and Parker,
K.K. “A Model of the Human 5HT1a Receptor/G Protein
Interface.” Presented at Soc. for Neurosci. Satellite
Meeting, Serotonin: From the Molecule to the Clinic; New
Orleans, LA, November 2000, #156.
Thiagaraj, H.V., Todd, C.L., Seaver, B.P., and Parker,
K.K.“Kinetic Properties of Human 5HT1a Receptor Intracellular
Loop Peptides.” Soc. for Neurosci. Absts. 26: 47.14, 2000.
Russo, E.B., Macarah, C.M., Thiagaraj, H.V., Medora, R.S.,
and Parker, K.K. “Activity of the Essential Oil of Hemp at
5HT1a and 5HT2a Receptors.” Am. Soc.Pharmacog. Absts. 41:
P174, 2000.
Ortiz, T.C., Devereaux, M.C., and Parker, K.K. “Coupling and
G Protein Activating Characteristics of a Human 5-HT1a
Receptor
i2 Loop Pepide.” Soc. for Neurosci. Absts. 25:
1466, 1999.
Bessac, B.F., Selvage, D.J., Ortiz, T.C., Parker, K.K., and
Johnston,
C.A.
“Immunocytochemical
Detection
of
Mineralocorticoid Receptor in Rat Arcuate Nucleus, But Not
Hippocampus.” Proc. West. Pharm. Soc. 42: 138, 1999.
Ortiz, T.C., Devereaux, M.C., and Parker, K.K. “Differential
Coupling and G Protein Activating Properties of Human 5-HT1a
Receptor I3 Loop Peptides.” Soc. for Neurosci. Absts. 24:
1096, 1998.
Ortiz, T.C., Parker, K.K., and Eyer, C.E.
"Differential
Activation of C6 Glioma Protein Kinase C Isoforms by a
Phorbol Ester and Trimethyltin." Proc. West. Pharmacol. Soc.
40: 155, 1997.
Ortiz, T.C., Hayataka, K., Braun, P., and Parker, K.K.
"Structure-Activity
Relationships
at
the
Human
5HT1a
Receptor/G Protein Interface." Soc. for Neurosci. Absts. 23:
128, 1997.
Parker, K.K., Colson, N., O'Connor, M.-F., Hayataka, K., and
Iverson, J. "Peptide Mediated Uncoupling of the Human 5HT1a
Receptor." Soc. for Neurosci. Absts. 22: 1324, 1996.
Colson, N., Hayataka, K., Weber, J., Russo, E., Medora, R.,
and Parker, K.K. "Comparative Pharmacology of Parthenolide at
Serotonin Receptors." Am. Soc. Pharmacog. Absts. 37: P123,
1996.
Weber, J.T., Hayataka, K., and Parker, K.K. "Pharmacological
Activity of Solubilized Human 5HT1a Receptors."
Soc. for
Neurosci. Absts. 21: 1854, 1995.
Weber, J., O'Connor, M.-F., and Parker, K. "Characterization
of 5HT1a Receptors from Rabbit Brain."
Proc. West.
Pharmacol. Soc. 38:, 1995.
Weber, J., Morlan, M., and Parker, K.K.
"Potential of Y79
Retinoblastoma as a Model Drug Screening System."
Proc.
Mont. Acad. Sci. 54:, 1994.
Smart, J., Rouse, C., Agrawal, D., and Parker, K.K. "Peptide
Growth Factors as Modulators of Differentiation in Glioma."
Proc. Mont. Acad. Sci. 53: 52, 1993.
Eyer, C.L., James, W.,
Manson, R., Smith, J.R.,
and
Parker, K.K.
"Determination of Glutamine Synthetase and
Catalase Activity in Late Passage C6 Glioma Cell Line."
Proc. West. Pharmacol. Soc. 35: 244, 1992.
Smart, J., Alexander, K., Parker,J., and Parker, K. "Clonal
and Environmental Factors in Transdifferentiation of C6
Glioma." Proc. Mont. Acad. Sci. 51: 44, 1991.
Parker, K.K. "Regulation of Differentiation in C6 Glioma."
Proc. Mont. Acad. Sci. 49: 168, 1989.
Parker, J.A., and Parker, K.K.
"New Approaches to AntiMigraine Drugs:
Pharmacognosy of Native American Medicinal
Plants." Am. Assoc. Adv. Sci., Jan. 1989.
Parker, J.A., and
Parker, K.K.
"Pharmacognosy of
Southwestern Montana:
Search for Migraine-Active Agents."
Am. Soc. Pharmacog. Absts. 27: , 1986.
Parker,
K.K.,
and
Trevor,
A.J.
"Structure-Activity
Relationships of Acetylcholinesterase Inhibitors."
Proc.
Mont. Acad. Sci. 45: 129, 1985.
Parker, K.K., and Wickstrom, E. “Structural Analysis of
Ribosomes with Oligoproline Molecular Rulers.”Proc. Mont.
Acad. Sci. 42: 49, 1983.
Parker, K., Norenberg, M., and Vernadakis, A.
"Effect of
Cortisol and cAMP on Glutamine Synthetase Activity." Trans.
Am. Soc. Neurochem. 11: 101, 1980.
Vernadakis, A., Norenberg, M., and Parker, K. "Differential
Glial Expression in Young and Old Passages of C-6 Glial
Cells." Int. Soc. Neurochem., Jerusalem, September 1979.
Parker, K., and Vernadakis, A.
"Stimulation of Ornithine
Decarboxylase Activity In Culture."
Trans. Am. Soc.
Neurochem. 10: 130, 1979.
Parker, K.,
Arnold, A., Strong, S., and Vernadakis, A.
"Maturational Profile of Ornithine Decarboxylase Activity in
Vivo and in Culture." The Pharmacologist 20: 272, 1978.
Parker, K.K., Chan, S.-L., and Trevor, A.J.
"Affinity
Chromatography of the 14S and 18S Forms of Acetylcholinesterase." Trans. Am. Soc. Neurochem. 8: 170, 1977.
Parker, K.K., Chan, S.-L., and Trevor, A.J. "Purification of
Acetylcholinesterase from Fresh Electric Organ by Affinity
Chromatography." The Pharmacologist 18: 146, 1976.
Reviews:
Parker, K.K. Review of "Nucleic Acid Structure and Synthesis," by
J.H.K. Parish. In J. Chem. Ed. 65: A298-299.
Solicited Publications:
Adams, J.D., Lien, E.J., and Parker, K.K. “Extracellular and
Intracellular Signaling-An Introduction.” In Intracellular
and Extracellular Signaling. Adams, J.D., and Parker, K.K.
(Eds.) Royal Society of Chemistry, Cambridge, Chap. 1, 1-9,
2011.
Parker, K.K. “Involvement of Adipokines in Migraine Headache.” In
Intracellular and Extracellular Signaling. Adams, J.D., and
Parker, K.K. (Eds.) Royal Society of Chemistry, Cambridge,
Chap.7, 116-129, 2011.
Contributor to: “Glossary for Chemists of Terms Used in
Toxicology.” Pure and Applied Chemistry 65 (9): 2003-2122,
1993.
Parker, K.K. “Psychoactive Drug Therapy.” In Magill’s Survey
of Social Sciences: Psychology. Salem Press, June 1993, pgs.
1891-1897.
Parker, K.K.
“Li Isolates the Human Growth Hormone.” In Great
Events from History II: Science and Technology. Salem Press,
August 1991, pgs. 1358-1362.
Parker, K.K.
"Wilkins Discovers Reserpine,
The First
Tranquilizer." In Great Events from History II: Science and
Technology. Salem Press, August 1991, pgs. 1353-1357.
Parker, K.K. "Wilkins Introduces Reserpine for the Treatment of
High Blood Pressure."
In Great Events from History II:
Science and Technology. Salem Press, Aug.1991, pgs. 14291433.
Parker, K.K. “Ochoa Creates Synthetic RNA.” In Great Events from
History II: Sci. and Tech. Salem Press, Aug.1991, pgs. 13631367.